Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE 3: Bosentan PK in Pediatric PAH
NCT01223352Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2011
- Primary completion
- Apr 2013
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of bosentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan at Week 4. Started Mar 2011; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01223352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01223352.